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Abstract
Purpose In patients treated with percutaneous coronary
intervention (PCI) with the paclitaxel-eluting stent, we
examined whether patient-rated health status predicts
adverse clinical events.
Methods Consecutive PCI patients treated with drug-eluting
stenting (N = 870; 72.2% men; mean age = 62.6 ± 11.5)
completed the EQ-5D post-PCI. The EQ-5D levels were
dichotomized into ‘no problems’ (level 1) versus ‘problems’
(levels2,3);thevisualanaloguescale(VAS)wasdichotomized
using the 25th percentile (cut-off B60) indicating poor health
status. Patients were followed up for 1-year clinical events
(death or non-fatal myocardial infarction (MI)).
Results There were 53 deaths/MIs at follow-up. The EQ-
5D health status dimensions mobility (HR:2.23; 95%
CI:1.25–3.97), self-care (HR:3.09; 95% CI:1.54–6.20), and
self-reported health status as measured with the EQ-VAS
(HR:2.94; 95% CI:1.65–5.25) were independent predictors
of death/MI and added to the predictive value of a model
comprised of demographic and clinical characteristics. The
EQ-5D dimensions usual activities, pain/discomfort, and
anxiety/depression were not associated with adverse clini-
cal events in adjusted analysis.
Conclusions Patient-rated health status predicted adverse
clinical events at 1-year follow-up in PCI patients treated
with drug-eluting stenting, with the risk being more than 2-
fold independent of disease severity and other demographic
and clinical characteristics. It may be timely to adopt
standard assessment of health status in clinical practice.
Keywords Health status  Mortality  Paclitaxel-eluting
stent  Percutaneous coronary intervention
Abbreviations
CABG Coronary artery bypass graft surgery
CAD Coronary artery disease
CCS Canadian Cardiovascular Society
COURAGE Clinical outcomes utilizing
revascularization and aggressive drug
evaluation trial
MI Myocardial infarction
NYHA Class New York Heart Association functional
class (I-IV)
PCI Percutaneous coronary intervention
VAS Visual analogue scale
Introduction
Health status, as reported by the patient, is gaining
increasing recognition as an important outcome measure in
cardiovascular disease that may help bridge the gap
between research and clinical practice [1]. Health status
may be used to optimize the quality of care and may also
aid in clinical decision-making and risk stratiﬁcation,
thereby enabling treatment recommendations to be tailored
to individual patients [1–3].
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DOI 10.1007/s11136-010-9775-5Patient-rated health status refers to the impact of disease
on patient symptoms, functional status and quality of life
[1, 2]. Alternative measures to health status exist, such as
New York Heart Association (NYHA) functional class to
assess the severity of heart failure and the Canadian
Cardiovascular Society (CCS) classiﬁcation to determine
the severity of angina pectoris, but they have been criti-
cized for their poor reproducibility and sensitivity to tap
treatment-related changes [4, 5]. Moreover, the NYHA
and CCS systems represent physician-rated measures, with
studies showing a discrepancy between physician-rated and
patient-rated health status, but also that physicians tend to
underestimate functional disabilities in patients [6, 7].
Patient-rated health status has also been shown to pre-
dict mortality and morbidity in patients with coronary
artery disease (CAD) [8] and heart failure [9, 10]. A recent,
systematic review indicates that in particular poor physi-
cal—but less so mental—health status is a signiﬁcant
predictor for poor prognosis, independent of indicators of
somatic disease severity and comorbidities [11]. However,
only one study focused on patients treated with percuta-
neous coronary intervention (PCI), and the latter study was
conducted prior to the introduction of drug-eluting stents in
general clinical practice [11]. Given that drug-eluting
stenting reduces the restenosis rate substantially [12],
which in turn may lead to improved health status and
quality of life, it is important to examine whether health
status also predicts prognosis in the drug-eluting stent era.
Hence, in the current study, we examined whether poor
health status, as measured with the brief and validated
EQ-5D [12], predicts clinical events at follow-up in a
consecutive series of patients treated with PCI with drug-
eluting stenting.
Materials and methods
Patients and design
In the period from 15 February 2005 to 14 February 2006,
all consecutive patients treated with PCI due to a myo-
cardial infarction (MI) or angina (unstable or stable) in the
Erasmus Medical Center Rotterdam, The Netherlands,
were asked to participate in the current study, if alive
1 month post-PCI. The paclitaxel-eluting stent was used as
the default strategy for patients undergoing PCI in our
institution during this period. We approached the municipal
civil registries in the ﬁrst month after the index PCI pro-
cedure to obtain survival status. If patients were still alive,
they were approached by mail and asked to complete the
EQ-5D, which is a brief, standardized and validated self-
report questionnaire that assesses health status as reported
by the patient [13]. Assessment 1 month post-PCI (referred
to as baseline in the remainder of the article) was in part
chosen due to logistic reasons, but concerns have also been
voiced that assessment of patient-centered outcomes, such
as health status and depression, too close to an acute car-
diac event may be more likely to reﬂect physical ill health
rather than true symptomatology [14]. If patients did not
return the questionnaire, they received a reminder via the
mail together with a new questionnaire.
The medical ethics committee of the Erasmus Medical
Center approved the study protocol. The study was carried
out in accordance with the Declaration of Helsinki, and all
patients provided written informed consent.
Materials
Demographic and clinical variables
Demographic variables included gender and age. Infor-
mation on clinical variables (i.e., indication for PCI (MI
versus stable/unstable angina), multi-vessel disease, pre-
vious MI, previous PCI, previous coronary artery bypass
graft surgery (CABG), hypertension, hypercholesterolemia,
and diabetes) and cardiac medication (i.e., aspirin, calcium
antagonists, beta-blockers, ACE inhibitors, statins, diuret-
ics, clopidogrel, and heparin) were retrieved from the
patients’ medical records. Smoking status was assessed by
means of self-report.
Health status
The EQ-5D, a generic measure of perceived health status
developed by the EuroQol Group, was used to assess
general health status in the current study [13]. The EQ-5D
consists of a visual analogue scale (VAS), with patients
rating their health status on a scale from 0 (worst imagin-
able health status) to 100 (best imaginable health status),
and a descriptive system comprising ﬁve questions
assessing the following domains: Mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression. Each
question can be scored as: having no problems (level 1),
some problems (level 2), or severe problems (level 3). In
addition, it is possible to calculate a utility score, a single
summary index derived on the basis of the EQ-5D
domains, with this information being useful in cost-utility
analysis. However, given that we did not compare two
treatment options and their associated costs, we did not use
the utility score in the current study. In the present study,
the VAS scale was dichotomized using the 25th percentile
(cut-off B 60) to indicate poor health status [8], while the
EQ-5D levels were dichotomized into ‘no problems’ (i.e.,
level 1) versus ‘problems’ (i.e., levels 2 and 3) [15]. Others
have also advocated the dichotomization of patient-cen-
tered outcomes, such as health status, in order to enhance
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123clinical interpretability [16]. The EQ-5D is a brief and
practical instrument, with satisfactory validity and reli-
ability for various diseases, including CAD, and for the
general population [17, 18].
Clinical endpoint
The clinical endpoint was deﬁned as death (all-cause) or
non-fatal MI at 1 year (median = 1.2 years), with follow-
up being complete for all patients. Survival status at 1 year
was obtained from municipal civil registries. Reinfarction
was diagnosed by recurrent symptoms and/or new elec-
trocardiographic changes in association with increases in
creatine kinase and creatine kinase myoglobin levels of[3
times the upper normal limit [19, 20]. A combined end-
point of death/non-fatal MI was used, due to the length of
the follow-up period, but also since a combined endpoint is
often used as a cardiovascular outcome measure. As the
principal regional cardiac referral center, repeat procedures
(percutaneous and surgical) are normally performed at our
institution and recorded prospectively in our database.
However, given that over 80% of the patients are referred
from hospitals in the area, and in order to ensure that all
MIs and repeat procedures were captured, patients were
asked by means of a postal survey at 1 year if they had
experienced an event during the follow-up period, with a
response rate of 75–80%. This information was veriﬁed
against the medical records, and if necessary via general
practitioners or referring cardiologists; 90–95% of all
patients with an event had responded to our postal survey.
Statistical analyses
Differences on nominal variables were compared with the
chi-square test (Fisher’s exact test when appropriate) and
with Student’s t-test for continuous variables. Unadjusted
and adjusted Cox proportional hazard regression analyses
were used to examine the impact of poor health status on
prognosis. Separate univariable and multivariable Cox pro-
portional hazard regression analyses were performed, enter-
ing each of the health status domains as the independent
variable, and the clinical endpointas the outcome (dependent
variable). Multivariable analyses were conducted using a
sequential modeling approach, entering demographic and
clinical characteristics (i.e., gender, age, indication for PCI,
multi-vessel disease, cardiac history (deﬁned as previous MI,
PCI, or CABG), comorbidities (deﬁned as hypertension,
hypercholesterolemia, or diabetes), smoking, and PCI or
CABG during the follow-up period) in the ﬁrst block and the
health status domain in question in the second block, in order
to determine whether the addition of health status added to
the level of prediction of the model. Kaplan–Meier curves
were generated to graphically present the time to death/MI
for patientswithpoor versus good health status. The log-rank
test was used to ascertain whether differences between
groups were statistically signiﬁcant. All tests were two-tailed
(P-value\.05); for Cox proportional hazard regression
analyses, hazard ratios (HR) and their corresponding 95%
conﬁdenceintervals(CI)arereported.Alldatawereanalyzed
using SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois).
Results
Non-participants versus participants on baseline
characteristics
A ﬂowchart of the patient selection for the current study is
presented in Fig. 1. Participants (n = 870) were more likely
to be older (mean age = 62.7 ± 11.5 vs. 60.2 ± 13.4;
P =.006), to have hypercholesterolemia (81.0% vs.
71.9%; P = .001), and to be prescribed aspirin (92.6% vs.
87.1%; P = .005) and clopidogrel (90.8% vs. 83.1%;
P\.001) compared to non-participants (n = 302). No
other statistically signiﬁcant differences were found
between participants and non-participants on demographic
and clinical baseline characteristics.
Baseline characteristics
There were 53 events (deaths = 39; MIs = 14) at follow-
up. During the follow-up period, 51 (5.9%) of patients
underwent a revascularization procedure (i.e., PCI or
CABG). Patient baseline characteristics for the total sample
and stratiﬁed by death/MI at follow-up are presented in
Table 1. Patients who experienced an event during follow-
up were likely to be older (mean age = 67.8 ± 9.8 vs.
N = 1238
Eligible patients 
treated with PCI in the 
study period
N =  66
Approached for 
participation in the study
N =  302
N =  1172
N = 870 
Refused participation
Responders (74.2%)* 
Died within 30 days
Fig. 1 Flowchart of patient selection for the current study. * Due to
missings on some of the EQ-5D dimensions, the number of patients
included in the analyses ranged from 870 to 814 patients, as follows:
Mobility (n = 870), self-care (n = 852), usual activities (n = 851),
pain (n = 846), anxiety/depression (n = 852), and VAS (n = 818)
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12362.3 ± 11.5; P = .001) and less likely to be prescribed
beta-blockers (41.5% vs. 62.9%; P = .003) and statins
(60.4% vs. 73.8%; P = .048) compared to patients without
an event. A trend was found for diabetes, with patients with
diabetes more likely to experience an event compared to
patients without diabetes (26.4% vs. 16.4%; P = .09).
Impact of health status on death/MI at follow-up
(unadjusted)
The Kaplan–Meier curves in Fig. 2 show the impact of the
EQ-5D health status domains on death/MI at follow-up, with
the associated incidence of events, hazard ratios, 95% CI
presented in Table 2. Poor mobility, poor self-care, and the
inability to perform usual activities were associated with an
increased risk of 1-year death/MI, with HRs ranging from 1.78
to3.90.Poorself-reportedhealthstatusontheEQ-5DVASwas
also a predictor of death/MI (HR: 2.76; 95% CI: 1.57–4.83;
P \ .001). The EQ-5D dimensions pain/discomfort and
anxiety/depression were not associated with prognosis.
Impact of health status on death/MI at follow-up
(adjusted)
In order to ascertain whether the impact of health status on
prognosis could be attributed to disease severity and other
demographic and clinical confounders, multivariable Cox
proportional hazard regression models were run separately
for the EQ-5D health status domains using a sequential
modeling approach, entering demographic and clinical
characteristics in the ﬁrst block and the health status domain
in question in the second block. In multivariable analyses,
poor mobility (HR: 2.23; 95% CI: 1.25–3.97; P = .006),
poorself-care(HR:3.09;95%CI:1.54–6.20,P = .002),and
poor self-reported health status as measured by the EQ-5D
VAS (HR: 2.94; 95% CI: 1.65–5.25; P\.001) remained
independent predictors of death/MI at follow-up, whereas
the inability to perform usual activities was no longer asso-
ciatedwithadverseclinicaloutcome(Table 3).Theaddition
of health status to a model comprised of demographic and
clinical characteristics (i.e., gender, age, indication for PCI,
multi-vesseldisease,cardiachistory(deﬁnedaspreviousMI,
PCI, or CABG), comorbidities (deﬁned as hypertension,
hypercholesterolemia, or diabetes), smoking, and PCI or
CABG during the follow-up period) added to the level of
prediction of the model as indicated by a signiﬁcant change
in the chi-square value comparedto the previous block, with
respect to poor mobility (v
2 = 7.441; df = 1; P = .006),
poor self-care (v
2 = 8.502; df = 1; P = .004), and poor
self-reported health status as measured by the EQ-5D VAS
(v
2 = 13.093; df = 1; P\.001) but not the other domains
(ps[0.05).
Table 1 Baseline
characteristics for the total
sample and stratiﬁed by death/
MI at follow-up
Results are presented as n (%),
unless otherwise indicated
MI Myocardial infarction, PCI
percutaneous coronary
intervention, CABG coronary
artery bypass graft surgery
a 140/90 mmHg or being
treated for hypertension
b C240 mg/dL or being treated
for hypercholesterolemia
c Being treated for diabetes
d Based on the patient’s self-
report
Total (n = 870) Event during
follow-up (n = 53)
No event during
follow-up (n = 817)
P
Demographics
Male gender 628 (72.2) 38 (71.7) 590 (72.2) 1.00
Age, mean ± SD 62.6 ± 11.5 67.8 ± 9.8 62.3 ± 11.5 .001
Clinical
MI as indication for PCI 290 (33.3) 23 (43.4) 267 (32.7) .15
Multi-vessel disease 416 (47.8) 30 (56.6) 386 (47.2) .24
Previous MI 226 (26.0) 13 (24.5) 213 (26.1) .93
Previous PCI 243 (27.9) 11 (20.8) 232 (28.4) .30
Previous CABG 74 (8.5) 3 (5.7) 71 (8.7) .61
Hypertension
a 379 (43.6) 23 (43.4) 356 (43.6) 1.00
Hypercholesterolemia
b 705 (81.0) 38 (71.7) 667 (81.6) .11
Diabetes
c 148 (17.0) 14 (26.4) 134 (16.4) .09
Smoking
d 216 (24.8) 18 (34.0) 198 (24.2) .15
Medication
Aspirin 806 (92.6) 49 (92.5) 757 (92.7) 1.00
Calcium antagonists 24 (2.8) 1 (1.9) 23 (2.8) 1.00
Beta-blockers 536 (61.6) 22 (41.5) 514 (62.9) .003
ACE inhibitors 330 (37.9) 17 (32.1) 313 (38.3) .45
Statins 635 (73.0) 32 (60.4) 603 (73.8) .048
Diuretics 87 (10.0) 5 (9.4) 82 (10.0) 1.00
Clopidogrel 790 (90.8) 47 (88.7) 743 (90.9) .76
Heparin 135 (15.5) 10 (18.9) 125 (15.3) .62
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123Discussion
In the current study, health status as reported by the patient
wasshowntopredictdeathorMIatfollow-upinPCIpatients
treated with drug-eluting stenting and to add to the level of
predictionofamodelcomprisedofdemographicandclinical
characteristics. The impact of health status on death/MI was
independent of disease severity and other demographic and
clinical characteristics known to predict major adverse
clinicalevents.Theriskincurredbypoormobility,poorself-
care, and poor self-rated health status as measured with the
EQ-5D VAS was more than twofold, whereas the EQ-5D
dimensions usual activities, pain/discomfort, and anxiety/
depression were not related to clinical outcome.
Similar to the Euro Heart Survey on coronary revascu-
larization conducted prior to the introduction of drug-
eluting stenting [8], we found that of the ﬁve descriptive
domains of the EQ-5D poor self-care was the most pow-
erful predictor of mortality and non-fatal MI, with the
adjusted risk being almost threefold. Self-care, comprising
an important part of the management of chronic conditions,
such as CAD, diabetes, and heart failure, refers to a set of
daily behaviors, including the monitoring of symptoms and
consulting a physician when necessary, performed by the
patient to manage his or her condition and to promote
health [21, 22]. Self-care and its impact on health outcomes
have received most attention in patients with heart failure
[21, 23]. This may be attributed to the chronicity of the
Fig. 2 Incidence of death/MI at
follow-up stratiﬁed by poor
health status. The number of
patients included in the analyses
varies between 845 and 870
across the health status domains,
as some patients had not
completed all items
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123condition and its associated functional impairments and
poor prognosis, with poor self-care more likely to have an
immediate impact on both functional status and quality of
life and prognosis in heart failure compared to more benign
conditions such as elective PCI due to stable CAD. How-
ever, the current results indicate that it is important also in
PCI patients to tend to the issue of self-care.
In the current study, poor mobility was also an important
and independent predictor of adverse clinical events at
follow-up. This ﬁnding is consistent with previous studies
showing that the extent of disability as perceived by the
patient predicts poor prognosis and quality of life both in
patients with CAD and heart failure, adjusting statistically
for indicators of disease severity, such as left ventricular
dysfunction and NYHA functional class [8, 11, 24–26].
This was also conﬁrmed in a recent systematic review on
the impact of patient-rated health status on mortality and
readmission in patients with CAD and heart failure [11].
The recent results of the Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation
(COURAGE) trial, randomizing patients with stable CAD
to either PCI with optimal medical therapy or optimal
medical therapy alone, testify to the utility of incorporating
a measure of health status in research and clinical practice
[2, 8]. Patients enrolled in the COURAGE trial with more
frequent anginal complaints, as assessed with the Seattle
Angina Questionnaire, derived the most beneﬁt from PCI
in combination with optimal medical therapy. Patients with
more severe anginal complaints would likely not be iden-
tiﬁed in clinical practice based on the clinician’s judgment
alone, in particular since physicians seem to underestimate
the disability of patients [6, 7]. Taken together with the
results of the current study, this indicates that assessment of
patients’ health status as part of routine clinical care may
be helpful in clinical decision-making and risk stratiﬁcation
and be instrumental in identifying high-risk patients who
may need more aggressive medical treatment and who
might also beneﬁt from adjunctive intervention to increase
adherence with lifestyle changes, such as exercising and
smoking cessation. Assessment of health status as part of
routine clinical practice would thus enable treatment rec-
ommendations to be tailored to individual patients. The
clinical utility of incorporating health status measures in
the clinical care and management of cardiac patients is
further elaborated upon in a seminal paper by Spertus [3]
and in a recent review of the impact of poor health
status on clinical outcomes in CAD and heart failure by
Mommersteeg and colleagues [11].
An advantage of using the EQ-5D as a measure of health
status in clinical practice is that it is brief and takes up little
time for patients to complete compared to other more
lengthy measures, such as the 36-item Short Form Health
Survey (SF-36), which is often used in CAD patients.
However, despite the prognostic value of the EQ-5D as
shown here and in another study [8], the instrument may be
less suitable to use as an outcome measure to tap treatment-
related changes, as it is likely to be less sensitive compared
to a disease-speciﬁc measure [11].
The results of the current study should be interpreted
with some caution due to the following limitations. First, a
Table 2 Impact of health status
on death/MI (unadjusted)
The number of patients included
in the analyses differs across the
health status domains, as some
patients had not completed all
items
EQ-VAS EQ visual analogue
scale
Event during
follow-up n (%)
No event during
follow-up n (%)
HR [95% CI] P
Mobility 2.50 [1.45–4.29] .001
No problems 24 (4.1) 565 (95.9)
Problems 29 (10.3) 252 (89.7)
Self-care 3.90 [2.05–7.44] \.001
No problems 40 (5.1) 749 (94.9)
Problems 12 (19.4) 50 (80.6)
Usual activities 1.78 [1.03–3.06] .04
No problems 25 (4.7) 506 (95.3)
Problems 27 (8.5) 292 (91.5)
Pain/discomfort 1.00 [0.58–1.74] .99
No problems 28 (5.9) 445 (94.1)
Problems 23 (6.2) 349 (93.8)
Anxiety/depression 0.84 [0.44–1.61] .60
No problems 40 (6.4) 586 (93.6)
Problems 12 (5.3) 213 (94.7)
EQ-VAS 2.76 [1.57–4.83] \.001
No problems 23 (4.0) 552 (96.0)
Problems 26 (10.7) 217 (89.3)
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123selection bias may have occurred, since patients who died
within the ﬁrst 1 month post-PCI did not have the oppor-
tunity to participate in the study, in turn limiting the gen-
eralizability of the ﬁndings. Second, we used the EQ-5D,
which is a generic rather than a disease-speciﬁc measure of
health status, since standardized and validated disease-
speciﬁc measures, such as the Seattle Angina Question-
naire (19 items) and the MacNew Quality of Life Ques-
tionnaire (27 items), tend to be longer. However, a disease-
speciﬁc measure is likely to be more sensitive to tap
symptoms that are important to patients. In addition, the
EQ-5D contains only one question tapping into the ﬁve
descriptive dimensions of mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression, which pro-
vides little room for variability in scores. Nevertheless, the
EQ-5D health status domains poor mobility and poor self-
care, and the EQ-5D VAS predicted adverse clinical events
despite adjustment for standard, biomedical risk factors.
Third, we had no information on renal failure, angina
severity, NYHA functional class, heart failure, left ven-
tricular ejection fraction, number of hospitalizations during
follow-up, participation in cardiac rehabilitation, socio-
economic status, and the use of psychotropic medication,
which could serve as potential confounders. However, we
did adjust for multi-vessel disease, as an indicator of
somatic disease severity. Fourth, the multivariable models
were not formally validated by means of the bootstrapping
method nor in a different, independent population, but the
results were consistent with the ﬁndings of Lenzen and
colleagues [8], who also examined the predictive validity
of the EQ-5D in patients treated with coronary revascu-
larization, although prior to the drug-eluting stent era.
In conclusion, several health status dimensions as
measured with the brief and validated EQ-5D predicted
death or non-fatal MI at follow-up in PCI patients treated
with drug-eluting stenting. The risk associated with poor
health status was more than twofold and was independent
of disease severity and other demographic and clinical
characteristics. To our knowledge, this is only the second
study to have examined the predictive validity of the EQ-
5D as a measure of health status in patients with CAD and
heart failure [11], and the ﬁrst study to show that poor
patient-rated health status predicts adverse clinical events
in PCI patients despite optimal treatment with drug-eluting
stenting. It may be timely to adopt standard assessment of
health status in clinical practice, given evidence from this
and other studies that patient-rated health status has unique
prognostic value.
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